Results 101 to 110 of about 119,907 (304)

Modulation of the LDL receptor and LRP levels by HIV protease inhibitors

Journal of Lipid Research, 2003
Inhibitors of the human immunodeficiency virus (HIV)-1 protease have proven to be effective antiretroviral drugs. However, patients receiving these drugs develop serious metabolic abnormalities, including hypercholesterolemia.
Huan Tran, Susan Robinson, Irina Mikhailenko, Dudley K. Strickland   +3 more
doaj  

Rhinosinusitis in HIV-infected children undergoing antiretroviral therapy [PDF]

, 2009
A associação dos inibidores de protease (IP) à terapia anti-retroviral provocou mudanças importantes na morbidade e mortalidade de pacientes infectados pelo HIV.
ARAÚJO-FILHO, Bernardo Cunha, MIZIARA, Ivan Dieb, PINHEIRO NETO, Carlos Diógenes, WEBER, Raimar   +3 more
core   +2 more sources

A gut microbiota‐bile acid axis inhibits the infection of an emerging coronavirus by targeting its cellular receptor aminopeptidase N

iMeta, EarlyView.
Bacteroides fragilis employs bile salt hydrolase to reprogram host bile acid metabolism, generating lithocholic acid that directly blocks porcine deltacoronavirus infection by disrupting spike protein‐aminopeptidase N binding, defining a microbiota‐bile acid antiviral axis with therapeutic potential against coronaviruses.
Ya‐Qing Zhang, Bin Wang, Yong‐Le Yang, Jin‐Xin Meng, Meng‐Di Zhang, Yi‐Ke Li, Bo Dong, Yanan Zhang, Bo‐Wen Liu, Dong Yang, Chun‐Miao Ji, Yao‐Wei Huang, Shu Jeffrey Zhu   +12 more
wiley   +1 more source

Reviewing HIV-1 Gag Mutations in Protease Inhibitors Resistance: Insights for Possible Novel Gag Inhibitor Designs

Molecules, 2019
HIV protease inhibitors against the viral protease are often hampered by drug resistance mutations in protease and in the viral substrate Gag. To overcome this drug resistance and inhibit viral maturation, targeting Gag alongside protease rather than ...
Chinh Tran-To Su, Darius Wen-Shuo Koh, Samuel Ken-En Gan   +2 more
doaj   +1 more source

Clinical Evaluation of Drug–Drug Interactions Between Bictegravir and Strong Inhibitors/Inducers of the CYP3A4, UGT1A1, or P‐gp Pathways

The Journal of Clinical Pharmacology, EarlyView.
Abstract In addition to antiretroviral therapy (ART), people with HIV often take medications to treat comorbidities. It is therefore important to assess these medications for potential drug‐drug interactions, which may affect the safety and efficacy of ART. Three phase I studies were conducted in adult participants without HIV. The pharmacokinetics (PK)
Priyanka Arora, Hui Liu, John Ling, Jason T. Hindman, Dhananjay D. Marathe   +4 more
wiley   +1 more source

Drogas anti-VIH: passado, presente e perspectivas futuras Drugs anti-HIV: past, present and future perspectives

Química Nova, 2003
Currently available anti-HIV drugs can be classified into three categories: nucleoside analogue reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs) and protease inhibitors (PIs).
Marcus Vinícius Nora de Souza, Mauro Vieira de Almeida   +1 more
doaj   +1 more source

Adaptive inhibitors of the HIV-1 protease

Progress in Biophysics and Molecular Biology, 2005
A significant obstacle to the efficacy of drugs directed against viral targets is the presence of amino acid polymorphisms in the targeted molecules. Amino acid polymorphisms may occur naturally due to the existence of variations within and between viral strains or as the result of mutations associated with drug resistance.
Ernesto Freire, Hiroyasu Ohtaka
openaire   +2 more sources

Bee products as alternatives in the treatment of viral infections

Journal of the Science of Food and Agriculture, EarlyView.
Abstract Medicines used in the treatment of viral infections usually reduce symptoms. There is a need to develop drugs that inhibit the viruses and do not merely relieve the symptoms. Natural bee products possess many pharmacological properties and are widely used in folk medicine. There are many studies on the antibacterial effects of bee products but
Michał Otręba, Łukasz Marek, Jerzy Stojko, Anna Rzepecka‐Stojko   +3 more
wiley   +1 more source

Effects of Sofosbuvir/Velpatasvir Therapy on Extrahepatic Manifestations in Patients With Type 2 Diabetes and Chronic Hepatitis C: Insights From a Nationwide Hepatitis C Virus Registry in Taiwan

The Kaohsiung Journal of Medical Sciences, EarlyView.
ABSTRACT This study examines the impact of hepatitis C virus (HCV) eradication through sofosbuvir/velpatasvir (SOF/VEL) treatment on glycated hemoglobin (HbA1c) levels in patients with chronic hepatitis C and type 2 diabetes mellitus (T2DM). Utilizing data from the Taiwan HCV Registry, a retrospective analysis was conducted on 2180 patients who met the
Szu‐Jen Wang, Te‐Sheng Chang, Ching‐Chu Lo, Chao‐Hung Hung, Chien‐Wei Huang, Lee‐Won Chong, Pin‐Nan Cheng, Ming‐Jong Bair, Ming‐Lun Yeh, Cheng‐Yuan Peng, Chien‐Yu Cheng, Jee‐Fu Huang, Chih‐Lang Lin, Chi‐Chieh Yang, Hsing‐Tao Kuo, Tsai‐Yuan Hsieh, Tzong‐Hsi Lee, Pei‐Lun Lee, Wen‐Chih Wu, Chih‐Lin Lin, Wei‐Wen Su, Sheng‐Shun Yang, Chia‐Chi Wang, Jui‐Ting Hu, Lein‐Ray Mo, Chun‐Ting Chen, Yi‐Hsiang Huang, Chun‐Chao Chang, Chia‐Sheng Huang, Guei‐Ying Chen, Chien‐Neng Kao, Chi‐Ming Tai, Chun‐Jen Liu, Mei‐Hsuan Lee, Pei‐Chien Tsai, Shu‐Chi Wang, Chia‐Yen Dai, Jia‐Horng Kao, Han‐Chieh Lin, Wang‐Long Chuang, Kuo‐Chih Tseng, Chi‐Yi Chen, Chung‐Feng Huang, Ming‐Lung Yu   +43 more
wiley   +1 more source

Discovery of Novel HIV Protease Inhibitors Using Modern Computational Techniques. [PDF]

Int J Mol Sci, 2022
Okafor SN, Angsantikul P, Ahmed H.
europepmc   +1 more source